Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling
نویسندگان
چکیده
منابع مشابه
Cell - free DNA: بیومارکر نوین تشخیص آزمایشگاهی
به انواع مختلف اسیدهای نوکلئیک آزاد در پلاسما شامل قطعات DNA ژنومی،DNA میتوکندریایی، DNA و mRNA های ویروسی و همچنین انواع miRNA اصطلاحا Cell–free nucleic acid گفته می شود. بخش مهمی از این اسیدهای نوکلئیک آزاد در پلاسما را Cell–free DNA (cfDNA) تشکیل می دهد. cfDNA به صورت قطعاتی با وزن مولکولی حدود KB 21-0.18 در سرم یا پلاسمای افراد سالم و افراد مبتلا به بسیاری از بیماری ها قابل تشخیص هستند. ...
متن کاملEffects of Preanalytical Factors on the Molecular Size of Cell-Free DNA in Blood, K.C
Cell-Free DNA in Blood, K.C. Allen Chan, Sze-Wan Yeung, Wing-Bong Lui, Timothy H. Rainer, and Y.M. Dennis Lo ( Department of Chemical Pathology and 2 Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, China; * address correspondence to this author at: Department of Chemic...
متن کاملEffects of preanalytical factors on the molecular size of cell-free DNA in blood.
also see Table 2 in the online Data Supplement). In HRT users, we found no significant differences in serum cobalamin or in plasma holoTC, MMA, and tHcy compared with controls. To our knowledge, there are currently no published data on the effects of HRT on plasma holoTC, and studies on serum cobalamin have not established a clear pattern (4, 5). We observed that HRT use decreased the risk of h...
متن کاملAdjustments to the preanalytical phase of quantitative cell-free DNA analysis
Evaluating the kinetics of cell-free DNA (cfDNA) in the blood of cancer patients could be a strong auxiliary component to the molecular characterization of cfDNA, but its potential clinical significance is obscured by the absence of an analytical consensus. To utilize quantitative cfDNA assessment with confidence, it is crucial that the preanalytical phase is standardized. In a previous publica...
متن کاملApplication of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions
Circulating tumor DNA (ctDNA) has emerged as a potential new biomarker with diagnostic, predictive, and prognostic applications for various solid tumor types. Before beginning large prospective clinical trials to prove the added value of utilizing ctDNA in clinical practice, it is essential to investigate the effects of various preanalytical conditions on the quality of cell-free DNA (cfDNA) in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Chemistry
سال: 2019
ISSN: 0009-9147,1530-8561
DOI: 10.1373/clinchem.2019.310854